MiNA Therapeutics Ltd has secured a new collaboration for its small activating RNA (saRNA) technology which can potentially restore normal cell function by activating gene expression. The partner is Servier of France which has agreed to pay up to €220 million for access to the technology to identify the first target for an undisclosed neurological disorder.
Small activating RNAs are short, double-stranded oligonucleotides that selectively increase gene transcription. Proponents of the technology say it can reach disease targets that are inaccessible with other approaches.